Complications of circulatory assist

Inhaled nitric oxide in cardiac surgery: Evidence or tradition?

“…Although device technology and clinical experience with RV failure management in this setting has led to reduced occurrence, the phenomenon remains important especially because the associated mortality remains high (91)(92)(93)(94). Figure 3 reproduces recent data on the development of early RV failure and its survival disadvantage in patients undergoing Heartmate II LVAD insertion.…”

Nonvalvular Cardiovascular Device–Related Infections

“…In a current case series, 62 85% of LVAD infections occurred when the device was left in place for Ͼ2 weeks. The incidence of infection has been highly variable among different surveys [63][64][65][66][67][68][69][70][71][72][73][74][75] and has been reported to range between 13% and 80%. The wide variability in infection risk is, in part, due to different types of infections that have been included under the category of LVAD-related infections.…”

Regional Differences in Utilization and Outcomes of Left Ventricular Assist Devices: Insights from the INTERMACS Registry

“…This is particularly relevant as a significant correlation has been shown between center experience and outcome particularly in DT patients. 26 Also, variables such as the use of preoperative risk score, and other factors, such as candidate selection bias which have been shown to be an important determinant of outcome in LVAD patients was not systematically examined in our study. 26 Adverse events in the early post-operative period have been linked to nearly 20% of overall mortality among LVAD patients.…”

“…26 Also, variables such as the use of preoperative risk score, and other factors, such as candidate selection bias which have been shown to be an important determinant of outcome in LVAD patients was not systematically examined in our study. 26 Adverse events in the early post-operative period have been linked to nearly 20% of overall mortality among LVAD patients. 7 Consistent with this observation, our study found that regardless of device strategy, regional differences in mortality were only significant in the early phase.…”